The Company continues to enroll people living with HIV in the multiple ascending dose part of a Phase 1 clinical trial with IMC-M113V, to identify a safe and tolerable dosing schedule. This study will also test whether IMC-M113V could lead to reduction in the viral reservoir and, after stopping all therapies delay or prevent HIV rebound. The MAD part of the trial will enroll up to 28 participants. The Company expects to present a data update from the Phase 1 clinical trial in the second half of 2024. In 2023, the Company amended the design of the ongoing Phase 1 trial with IMC-I109V for people living with HBV to include HBV-positive hepatocellular carcinoma. The Company continues to enroll patients into the trial in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
- Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
- 3 Best Stocks to Buy Now, 11/21/2023, According to Top Analysts
- Immunocore reinstated with an Overweight at JPMorgan
- Immunocore price target lowered to $72 from $74 at Mizuho
